对乙胆受体-抗体一般化肌痛性骨髓灰质炎亚型中efgartigimod治疗反应的模式和预测因素

相关实验视频

Updated: May 27, 2025

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Lei Jin¹, Zhangyu Zou², Qinzhou Wang³

¹Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.

Therapeutic advances in neurological disorders

|February 20, 2025

概括

在一般化肌痛性骨髓灰质炎亚型中,efgartigimod显示出不同的反应. 晚期发作的MG患者与早期发作和胸腺瘤相关的亚型相比,经历了更持续的症状控制.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

一般化肌痛性肌痛症 (gMG) 是一种严重的自身免疫性疾病.
Efgartigimod 是一种已批准的生物治疗gMG.
在乙胆受体gMG (AChR-gMG) 亚型之间存在治疗反应的变化.

研究的目的:

为了研究efgartigimod在ACHR-gMG亚型中的治疗反应模式.
为了确定对efgartigimod治疗反应的预测因素.

主要方法:

在中国对116名ACHR-gMG患者进行前性观察研究.
患者接受了efgartigimod,至少进行了20周的随访.
通过MG-ADL得分定义的最小症状表达 (MSE) 响应者;分析的亚型:EOMG,LOMG,TAMG.

主要成果:

30.2%的患者实现了MSE反应,在LOMG (42.9%) 中最高.
LOMG显示了更显著的MG-ADL得分减少和持续的症状控制.
基线MG-ADL得分是反应的独立预测指标.

结论:

对efgartigimod的治疗反应在ACHR-gMG亚型之间有所不同.
LOMG患者可能会从efgartigimod中获得更持久的益处.
这些发现支持生物时代对gMG的个性化治疗方法.

关键词:

这是早期发病的.在efgartigimod中使用.一般化骨髓灰质炎 (Myasthenia Gravis) 的发生.晚期开始的晚期开始的治疗反应的治疗反应.蒂莫莫马马 (thymomaoma) 是一种疾病.

更多相关视频

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...